MCID: CHR417
MIFTS: 66

Chronic Graft Versus Host Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Chronic Graft Versus Host Disease

Summaries for Chronic Graft Versus Host Disease

NIH Rare Diseases : 53 Chronic graft versus host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms may include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. The exact cause of chronic GVHD is unknown. It likely results from a complex immune-mediated interaction between the donor and recipient cells. Chronic GVHD is treated with prednisone or other similar anti-inflammatory or immunosuppressive medications.  

MalaCards based summary : Chronic Graft Versus Host Disease, also known as chronic graft-versus-host disease, is related to graft-versus-host disease and hematopoietic stem cell transplantation. An important gene associated with Chronic Graft Versus Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Azacitidine and Decitabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are muscle weakness and dysphagia

Related Diseases for Chronic Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Chronic Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 374)
# Related Disease Score Top Affiliating Genes
1 graft-versus-host disease 32.0 IFNG IL10 IL1A TNF
2 hematopoietic stem cell transplantation 31.3 IFNG IL10 TNF
3 bronchiolitis 30.7 IFNG IL10 TNF
4 bronchiolitis obliterans 30.7 IFNG IL10 TNF
5 erythema multiforme 30.4 IFNG TNF
6 pure red-cell aplasia 30.3 ALB IL2RA
7 large granular lymphocyte leukemia 30.1 IFNG IL2RA
8 acute graft versus host disease 30.1 IFNG IL10 IL2RA TNF
9 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.0 IFNG IL10 TNFSF13B
10 scabies 30.0 IL10 IL1A
11 chronic inflammatory demyelinating polyradiculoneuropathy 30.0 ALB IFNG
12 protein-losing enteropathy 29.9 ALB CD79A
13 aspergillosis 29.9 IFNG IL10 TNF
14 viral infectious disease 29.8 IFNG IL10 TNF
15 myeloma, multiple 29.8 ALB CD36 TNF TNFSF13B
16 polyradiculoneuropathy 29.8 ALB IFNG IL10
17 multiple sclerosis 29.7 IFNG IL10 IL2RA TNF TNFSF13B
18 hepatitis b 29.7 ALB IFNG TNF
19 hemophagocytic lymphohistiocytosis 29.7 IFNG IL10 IL2RA TNF
20 extrinsic allergic alveolitis 29.7 ALB IL10 IL2RA
21 autoimmune disease 29.7 CD79A IFNG IL10 IL2RA TNF TNFSF13B
22 alopecia areata 29.6 IFNG IL1A IL2RA TNF
23 membranous nephropathy 29.6 ALB CD79A TNF
24 hepatitis a 29.5 ALB IFNG IL10 TNF
25 uveitis 29.5 IFNG IL10 IL1A IL2RA TNF
26 keratoconjunctivitis sicca 29.4 ALB CD79A IL10 IL1A TNF
27 parotitis 29.4 ALB CD79A
28 arthritis 29.3 IFNG IL10 IL1A MICA TNF
29 psoriasis 29.3 IFNG IL10 IL1A MICA TNF
30 systemic lupus erythematosus 29.3 ALB CD79A IFNG IL10 IL2RA TNF
31 rheumatoid arthritis 29.3 IFNG IL10 IL1A IL2RA TNF TNFSF13B
32 leukemia 10.6
33 polymyositis 10.4
34 hepatitis 10.3
35 lichen planus 10.3
36 buruli ulcer 10.3 IFNG IL10
37 tuberculoid leprosy 10.3 IFNG IL10
38 hand, foot and mouth disease 10.3 IFNG IL10
39 fungal meningitis 10.3 IFNG IL10
40 peanut allergy 10.3 IFNG IL10
41 pericardial tuberculosis 10.3 IFNG IL10
42 chronic active epstein-barr virus infection 10.3 IFNG IL10
43 primary peritoneal carcinoma 10.3 IFNG IL10
44 nephrotic syndrome 10.3
45 ascaris lumbricoides infection 10.3 IFNG TNFSF13B
46 spondylocarpotarsal synostosis syndrome 10.3
47 cryptococcal meningitis 10.3 IFNG TNFSF13B
48 milk allergy 10.2 CD79A IL10
49 folliculitis 10.2 IFNG IL2RA
50 lymphocytic leukemia 10.2

Graphical network of the top 20 diseases related to Chronic Graft Versus Host Disease:



Diseases related to Chronic Graft Versus Host Disease

Symptoms & Phenotypes for Chronic Graft Versus Host Disease

Human phenotypes related to Chronic Graft Versus Host Disease:

59 32 (show top 50) (show all 55)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0001324
2 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
3 arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001369
4 flexion contracture 59 32 occasional (7.5%) Occasional (29-5%) HP:0001371
5 gastroesophageal reflux 59 32 occasional (7.5%) Occasional (29-5%) HP:0002020
6 photophobia 59 32 frequent (33%) Frequent (79-30%) HP:0000613
7 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
8 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
9 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
10 pancytopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001876
11 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
12 nail dystrophy 59 32 frequent (33%) Frequent (79-30%) HP:0008404
13 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
14 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
15 skin ulcer 59 32 occasional (7.5%) Occasional (29-5%) HP:0200042
16 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
17 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
18 keratoconjunctivitis sicca 59 32 frequent (33%) Frequent (79-30%) HP:0001097
19 hematuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000790
20 xerostomia 59 32 frequent (33%) Frequent (79-30%) HP:0000217
21 recurrent infections 59 32 frequent (33%) Frequent (79-30%) HP:0002719
22 chest pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0100749
23 diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002014
24 erythema 59 32 frequent (33%) Frequent (79-30%) HP:0010783
25 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
26 abnormality of skin pigmentation 59 32 frequent (33%) Frequent (79-30%) HP:0001000
27 bronchiectasis 59 32 frequent (33%) Frequent (79-30%) HP:0002110
28 skin vesicle 59 32 occasional (7.5%) Occasional (29-5%) HP:0200037
29 pneumothorax 59 32 occasional (7.5%) Occasional (29-5%) HP:0002107
30 pleural effusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0002202
31 pulmonary infiltrates 59 32 occasional (7.5%) Occasional (29-5%) HP:0002113
32 fasciitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100537
33 poor wound healing 59 32 hallmark (90%) Very frequent (99-80%) HP:0001058
34 nausea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002018
35 onycholysis 59 32 frequent (33%) Frequent (79-30%) HP:0001806
36 esophageal ulceration 59 32 occasional (7.5%) Occasional (29-5%) HP:0004791
37 urinary bladder inflammation 59 32 occasional (7.5%) Occasional (29-5%) HP:0100577
38 food intolerance 59 32 frequent (33%) Frequent (79-30%) HP:0012537
39 phimosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001741
40 esophageal stricture 59 32 occasional (7.5%) Occasional (29-5%) HP:0002043
41 wheezing 59 32 occasional (7.5%) Occasional (29-5%) HP:0030828
42 obstructive lung disease 59 32 occasional (7.5%) Occasional (29-5%) HP:0006536
43 morphea 59 32 occasional (7.5%) Occasional (29-5%) HP:0012344
44 recurrent corneal erosions 59 32 frequent (33%) Frequent (79-30%) HP:0000495
45 intermittent generalized erythematous papular rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0007432
46 bronchiolitis obliterans 59 32 occasional (7.5%) Occasional (29-5%) HP:0011946
47 entrapment neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0012181
48 elevated hepatic transaminases 59 Frequent (79-30%)
49 pain 59 Occasional (29-5%)
50 thickened skin 59 Very frequent (99-80%)

MGI Mouse Phenotypes related to Chronic Graft Versus Host Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.92 CD36 CD79A IFNG IL10 IL1A IL2RA
2 digestive/alimentary MP:0005381 9.88 ALB CD36 IFNG IL10 IL2RA TNF
3 homeostasis/metabolism MP:0005376 9.86 ALB CD36 CD79A IFNG IL10 IL1A
4 endocrine/exocrine gland MP:0005379 9.85 ALB CD36 IFNG IL10 IL2RA TNF
5 immune system MP:0005387 9.76 CD36 CD79A IFNG IL10 IL1A IL2RA
6 liver/biliary system MP:0005370 9.43 ALB CD36 CD79A IFNG IL10 TNF
7 neoplasm MP:0002006 9.1 ALB CD79A IFNG IL10 IL1A TNF

Drugs & Therapeutics for Chronic Graft Versus Host Disease

Drugs for Chronic Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 351)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azacitidine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 320-67-2 9444
2
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
3
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3, 179045-86-4
4
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
5
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
6
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
8
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
9
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
10
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
11
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 147-94-4 6253
12
Foscarnet Approved Phase 4,Phase 2 63585-09-1, 4428-95-9 3415
13
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 82410-32-0 3454
14
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
15
Infliximab Approved Phase 4,Phase 3,Phase 2 170277-31-3
16
Iron Approved Phase 4 7439-89-6 23925
17
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
18
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-30-3 6037
20
Phosphonoacetic Acid Experimental Phase 4,Phase 2 4408-78-0 546
21
Treosulfan Investigational Phase 4,Phase 3,Phase 2,Phase 1 299-75-2 9296
22 Semustine Experimental, Investigational Phase 4,Phase 2,Phase 3 13909-09-6
23 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Folate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
34 Cyclosporins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
38 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Thymoglobulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Reverse Transcriptase Inhibitors Phase 4,Phase 2
49 Ganciclovir triphosphate Phase 4,Phase 3,Phase 2,Not Applicable
50 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 900)
# Name Status NCT ID Phase Drugs
1 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
2 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
3 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
4 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
5 Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4 deferasirox
6 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
7 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4 anti thymoglobulin
8 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
9 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
10 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
11 ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
12 PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil
13 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
14 Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
15 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Unknown status NCT01295710 Phase 3
16 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
17 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
18 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
19 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
20 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
21 Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
22 MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
23 Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma Unknown status NCT00998270 Phase 2, Phase 3
24 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
25 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);Cyclosporin, Methotrexate (GVHD prophylaxis)
26 MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment Unknown status NCT02240992 Phase 2, Phase 3
27 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
28 TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID Unknown status NCT02327351 Phase 2, Phase 3
29 Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia Unknown status NCT00342316 Phase 3
30 Haplo-SCT vs ASCT With or Without Decitabine in AML CR1 Unknown status NCT02059720 Phase 3
31 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
32 Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Completed NCT01106833 Phase 2, Phase 3 Sirolimus + calcineurin inhibitor + prednisone;Sirolimus + prednisone
33 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
34 Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease Completed NCT01699412 Phase 3 Clobetasol;Dexamethasone
35 Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease Completed NCT00031824 Phase 3 cyclosporine;hydroxychloroquine;prednisone;tacrolimus
36 Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML Completed NCT01191957 Phase 3 Busulphan plus Cyclophosphamide;Busulphan plus Fludarabine
37 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
38 Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation Completed NCT01020175 Phase 3
39 Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD) Completed NCT00887263 Phase 3 Budesonide;Placebo
40 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
41 Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
42 Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation Completed NCT00130754 Phase 3 Thymoglobuline
43 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
44 Nonmyeloablative Stem Cell Transplant in Elderly Completed NCT00382759 Phase 2, Phase 3
45 Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation Completed NCT01530581 Phase 3
46 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
47 Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA Completed NCT00455312 Phase 2, Phase 3 Campath 1H;Cyclophosphamide;Fludarabine;antithymocyte globulin;Methylprednisolone
48 Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies Completed NCT00275678 Phase 3
49 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3 maribavir
50 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Completed NCT00075816 Phase 3

Search NIH Clinical Center for Chronic Graft Versus Host Disease

Genetic Tests for Chronic Graft Versus Host Disease

Anatomical Context for Chronic Graft Versus Host Disease

MalaCards organs/tissues related to Chronic Graft Versus Host Disease:

41
T Cells, Bone, Bone Marrow, Skin, Eye, B Cells, Liver

Publications for Chronic Graft Versus Host Disease

Articles related to Chronic Graft Versus Host Disease:

(show top 50) (show all 1055)
# Title Authors Year
1
HSCT-GAVE as a Manifestation of Chronic Graft versus Host Disease: A Case Report and Review of the Existing Literature. ( 29721346 )
2018
2
Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria. ( 29330402 )
2018
3
Full-body physical therapy evaluation for pre- and post-hematopoietic cell transplant patients and the need for a modified rehabilitation musculoskeletal specific grading system for chronic graft-versus-host disease. ( 29348574 )
2018
4
Topical vitamin D analog for chronic graft versus host disease of the skin. ( 29335622 )
2018
5
Novel management of vaginal chronic graft-versus-host disease causing haematometra and haematocolpos. ( 29705733 )
2018
6
Chronic graft versus host disease presenting as lichen planus pigmentosus. ( 29410549 )
2018
7
A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment. ( 29752810 )
2018
8
Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease. ( 29740177 )
2018
9
Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. ( 29363541 )
2018
10
TGF-I^-Induced CD8<sup>+</sup>CD103<sup>+</sup>Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells. ( 29441062 )
2018
11
Renal Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: InvolvementA ofA Chronic Graft-Versus-Host Disease. ( 29854984 )
2018
12
Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. ( 29330403 )
2018
13
Total hysterectomy as hematocolpos treatment following bone marrow transplant. A rare complication of chronic graft-versus-host disease. ( 29329824 )
2018
14
Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. ( 29348127 )
2018
15
A phase II/III randomized, multicenter trial of Prednisone /Sirolimus vs Prednisone/Sirolimus/Calcineurin Inhibitor for treatment of chronic graft-versus-host disease: BMT CTN 0801. ( 29954931 )
2018
16
Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease. ( 29670626 )
2018
17
Patient-reported outcomes and health status associated with chronic graft-versus-host disease. ( 29858386 )
2018
18
Vitiligo type cutaneous manifestation of chronic graft-versus-host disease. Case report. ( 29664513 )
2018
19
Correction: Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. ( 29771974 )
2018
20
Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease. ( 29959747 )
2018
21
Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. ( 29758393 )
2018
22
Griscelli Syndrome with Fibronodular Sclerodermatous Chronic Graft Versus Host Disease. ( 29398817 )
2018
23
Circulating monocyte subsets in human chronic graft-versus-host disease. ( 29728699 )
2018
24
B-cell targeting in chronic Graft-versus-Host disease. ( 29437591 )
2018
25
Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease. ( 29788024 )
2018
26
Permanent alopecia as a manifestation of chronic graft-versus-host disease of the scalp: clinical, dermoscopic and histopathological observations. ( 29876958 )
2018
27
Ocular Surface and Tear Film Characteristics in a Sclerodermatous Chronic Graft-Versus-Host Disease Mouse Model. ( 29341972 )
2018
28
Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. ( 29425517 )
2018
29
Chronic Graft-versus-Host Disease: A Long Road Ahead. ( 29353108 )
2018
30
Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. ( 29947972 )
2018
31
Overcoming human disagreement assessing erythematous lesion severity on 3D photos of chronic graft-versus-host disease. ( 29740182 )
2018
32
Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation. ( 29692783 )
2018
33
Biomarkers in chronic graft-versus-host disease: quo vadis? ( 29367715 )
2018
34
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. ( 29367708 )
2018
35
Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy. ( 29911695 )
2018
36
Longstanding alopecia and nail dystrophy are associated with more severe overall chronic graft-versus-host disease in adults. ( 30214010 )
2018
37
Bilateral Adrenal Hemorrhage in a Patient with Antiphospholipid Syndrome during Chronic Graft-versus-host Disease. ( 29279512 )
2018
38
Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective. ( 29254596 )
2018
39
Long-Term Topical Diquafosol Tetrasodium Treatment of Dry Eye Disease Caused by Chronic Graft-Versus-Host Disease: A Retrospective Study. ( 29280750 )
2018
40
New and emerging therapies for acute and chronic graft versus host disease. ( 29317998 )
2018
41
Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. ( 29476954 )
2018
42
Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease. ( 29496562 )
2018
43
Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease. ( 29501781 )
2018
44
MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. ( 29530952 )
2018
45
Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease. ( 29540850 )
2018
46
Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graft-versus-host disease. ( 29542126 )
2018
47
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. ( 29549175 )
2018
48
Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib. ( 29549292 )
2018
49
Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. ( 29549412 )
2018
50
Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. ( 29550629 )
2018

Variations for Chronic Graft Versus Host Disease

Expression for Chronic Graft Versus Host Disease

Search GEO for disease gene expression data for Chronic Graft Versus Host Disease.

Pathways for Chronic Graft Versus Host Disease

Pathways related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 CD36 CD79A IFNG IL10 IL1A IL2RA
2
Show member pathways
13.53 IFNG IL10 IL1A IL2RA TNF TNFSF13B
3
Show member pathways
13.39 IFNG IL10 IL1A IL2RA TNF TNFSF13B
4
Show member pathways
13.16 IL10 IL1A IL2RA TNF TNFSF13B
5
Show member pathways
13.15 CD36 IFNG IL10 IL1A IL2RA TNF
6
Show member pathways
13.07 CD79A IFNG IL1A IL2RA TNF
7
Show member pathways
12.67 IFNG IL1A IL2RA TNF
8
Show member pathways
12.51 CD79A IFNG IL10 IL2RA TNF
9
Show member pathways
12.47 IFNG IL10 IL1A IL2RA TNF
10
Show member pathways
12.44 IFNG IL10 IL1A IL2RA MICA TNF
11
Show member pathways
12.35 IFNG IL10 IL1A TNF
12 12.25 CD79A IFNG IL10 IL2RA TNF TNFSF13B
13
Show member pathways
12.22 ALB IFNG TNF
14
Show member pathways
12.18 IFNG IL10 IL1A TNF
15
Show member pathways
12.16 CD36 IL1A TNF
16 12.15 IFNG IL10 IL1A TNF
17
Show member pathways
12.13 IFNG IL10 IL1A IL2RA TNF
18
Show member pathways
12.11 IFNG IL1A TNF
19 12.08 IL10 IL1A TNF
20 12 IFNG IL1A TNF
21
Show member pathways
11.96 IFNG IL10 TNF
22
Show member pathways
11.96 IFNG IL10 IL1A IL2RA TNFSF13B
23 11.95 IFNG IL1A TNF
24
Show member pathways
11.94 CD36 IFNG TNF
25 11.89 IFNG IL1A TNF TNFSF13B
26 11.84 CD36 IL10 IL1A TNF
27 11.81 IFNG IL10 TNF
28 11.78 IFNG IL10 IL2RA
29 11.74 CD36 IL1A IL2RA TNF
30
Show member pathways
11.71 IFNG IL2RA TNF
31 11.7 IL10 IL1A TNF
32 11.69 IFNG IL10 TNF
33 11.69 IFNG IL1A TNF TNFSF13B
34
Show member pathways
11.61 IFNG IL1A TNF
35 11.61 IFNG IL10 IL2RA TNF
36
Show member pathways
11.59 IFNG IL2RA TNF
37 11.52 CD36 IFNG IL10 TNF
38 11.49 IL10 IL1A TNF
39 11.46 IFNG IL10 IL2RA
40 11.44 IFNG IL1A TNF
41 11.31 CD36 IFNG IL10 TNF
42 11.3 IFNG IL10 TNF
43 11.29 IL10 IL1A TNF
44 11.23 IFNG IL2RA
45 11.22 IFNG TNF
46
Show member pathways
11.17 IFNG IL2RA
47 11.16 CD36 CD79A IFNG IL10 IL2RA TNF
48 11.15 IFNG IL2RA
49 11.13 IL10 IL1A TNF TNFSF13B
50 11.12 IFNG IL10

GO Terms for Chronic Graft Versus Host Disease

Cellular components related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.46 CD36 IL2RA MICA TNF
2 membrane raft GO:0045121 9.43 CD36 CD79A TNF
3 external side of plasma membrane GO:0009897 9.26 CD36 CD79A IL2RA TNF
4 extracellular space GO:0005615 9.23 ALB CD36 IFNG IL10 IL1A MICA

Biological processes related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.84 CD36 IFNG IL1A TNF
2 cell surface receptor signaling pathway GO:0007166 9.81 CD36 CD79A IFNG IL2RA
3 regulation of signaling receptor activity GO:0010469 9.8 IFNG IL10 IL1A TNF TNFSF13B
4 cellular response to lipopolysaccharide GO:0071222 9.76 CD36 IL10 TNF
5 B cell proliferation GO:0042100 9.62 CD79A IL10
6 negative regulation of interleukin-6 production GO:0032715 9.62 IL10 TNF
7 regulation of synapse organization GO:0050807 9.61 IL10 TNF
8 positive regulation of interleukin-12 production GO:0032735 9.61 CD36 IFNG
9 positive regulation of nitric oxide biosynthetic process GO:0045429 9.61 CD36 IFNG TNF
10 positive regulation of protein complex assembly GO:0031334 9.6 IFNG TNF
11 protein import into nucleus, translocation GO:0000060 9.59 IFNG TNF
12 positive regulation of osteoclast differentiation GO:0045672 9.58 IFNG TNF
13 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.57 IFNG TNF
14 regulation of regulatory T cell differentiation GO:0045589 9.56 IFNG IL2RA
15 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.55 IL10 TNF
16 cytokine-mediated signaling pathway GO:0019221 9.55 CD36 IL10 IL1A IL2RA TNF
17 endothelial cell apoptotic process GO:0072577 9.52 IL10 TNF
18 negative regulation of cytokine secretion involved in immune response GO:0002740 9.49 IL10 TNF
19 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 IFNG TNF
20 receptor biosynthetic process GO:0032800 9.46 IL10 TNF
21 positive regulation of cytokine secretion GO:0050715 9.43 IL10 IL1A TNF
22 positive regulation of blood microparticle formation GO:2000334 9.37 CD36 TNF
23 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 IFNG TNF
24 immune response GO:0006955 9.23 CD36 IFNG IL10 IL1A IL2RA MICA
25 negative regulation of growth of symbiont in host GO:0044130 9.13 CD36 IL10 TNF

Molecular functions related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.65 ALB CD36 CD79A IFNG IL10 IL1A
2 tumor necrosis factor receptor binding GO:0005164 9.16 TNF TNFSF13B
3 cytokine activity GO:0005125 9.02 IFNG IL10 IL1A TNF TNFSF13B

Sources for Chronic Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....